Considering that these pro-tumorigenic component states (i.e., desmoplastic fibroblast, osteoblast, and CTSK+ macrophage) negatively impact immunotherapy responses across different cancer types, alternative treatment strategies should be pursued for patients with pro-tumorigenic ecosystems. This evidence concerns the gene CTSK and cancer.